|
Celebrating Our 50th Anniversary
2012 marks the 50th anniversary of the Gibco® brand of cell culture products. With a rich heritage of dependability, consistency, and superior quality, Gibco® media, sera, cells, reagents, and supplements represent the industry standard in cell culture. Our goal is to provide scientists the means and the confidence to elevate research and healthcare now and in the future. We sincerely appreciate your loyalty, and are extremely proud to support your achievements thus far and the many yet to come.
Come back to this page all year to celebrate with us.
The History of Gibco |
Celebrate With UsCheck out what's new in cell culture and get a gift. BPI Europe Cell Culture Engineering XIII ISCT Annual Meeting Cell Line Development & Engineering BPI China |
Gibco® Promotions
Place your qualifying Gibco® product order to get a free Kindle Fire™ device or take advantage of other exclusive discounts. Learn more. |
Gathering Light Game App
Refresh yourself with the new Gathering Light game app for iPhone® and iPad® devices. |
Cell Culture Innovations
Achieve a higher return on investments from molecule to market with faster, easier, smarter solutions. See what's new |
Gibco® Hero of the Month

John C. H. Fann, Ph.D.
Associate Director, Cell Culture
Process Sciences
Abbott Bioresearch Center
When did you first get interested in science? What inspired you?
I have always been interested in science-related topics, even as a child. Chemistry and biology had been my two favorite subjects in school, and so when it came to choosing a major in college, it was natural for me to pick biochemistry. The field of life sciences was blooming rapidly in the 80‘s, and I was astonished at the new discoveries in molecular biology and protein chemistry that were occurring on an almost daily basis.
I first became familiar with cell culture technology as a graduate student at the National Taiwan University. The ideas of how genes and proteins control cell behavior and expression, and how external environments and nutrients affect the life cycle of a cell were fascinating to me. This fascination eventually led me towards a career in industrial cell culture development.
What are three highlights of your scientific journey?
My original goal was to embark on an academic route, which was the most common pathway for biochemistry graduates in the early 90’s. However, my first exposure to biotech industry came before I went abroad for my Ph.D. studies. I had worked at a Taiwanese vaccine company for a few years and while there, I was a part of the technology transfer team working with a U.S.-based biotech company. Through this opportunity, I learned the concept of using Chinese hamster ovary (CHO) cells for recombinant protein production and understood its potential in the biotech industry.
After working for a few biotech firms, I joined Abbott 10 years ago and have since participated in most of its commercial and clinical biopharmaceutical projects. I consider myself to be very fortunate to lead a group of talented scientists/engineers, who assist me in my continuing journey to develop the optimal cell line and process as part of our efforts of producing better biotherapeutics for human beings.
What is your future outlook on the next fifty years?
It was not predictable 50 years ago that recombinant human proteins could one day be produced and used for therapeutic purposes. Therefore, I believe it is impossible to accurately predict where the world will be 50 years from now. However, at least for the next decade, the biopharmaceutical industry will likely become more platform-driven so that the development timeline to initiate clinical trial can be greatly shortened.
More high-throughput technologies would continue to be introduced to accelerate the development of multiple candidate drugs. Biomanufacturing would adopt more automation to minimize the operation cost and maximize the product consistency. With the implementation of “Quality by Design” (QbD) and well-defined raw materials for both upstream and downstream processes, I believe the industry would gain better control on the product quality to further ensure the safety and efficacy of drug products. Besides, we may see more and more personalized medicines available on the market for individual needs. Finally, the industry would continue to strive towards higher productivity and yield processes, which will not only bring the cost of production down, but also introduce more affordable protein therapeutics to the general public.



